Rivaroxaban Monotherapy in Patients With Atrial Fibrillation After Coronary Stenting
Authors:
- 1 November 2021
- journal article
- research article
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 14 (21) , 2330-2340
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca
- Dainippon Sumitomo Pharma
- Japan Cardiovascular Research Foundation
- Sanofi
- Astellas Pharma
- Bayer Yakuhin
- Takeda Pharmaceutical Company
- Japan Cardiovascular Research Foundation
- Amgen K.K
- Otsuka Pharmaceutical
- Abbott Japan
- Boehringer Ingelheim Japan
- Bristol-Myers Squibb (20K08451)
- Ministry of Education, Culture, Sports, Science and Technology
- Merck Sharp and Dohme United Kingdom
- Abbott Laboratories
- Japan Agency for Medical Research and Development
This publication has 19 references indexed in Scilit:
- 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial FibrillationJACC, 2019
- Major Bleeding Rates in Atrial Fibrillation Patients on Single, Dual, or Triple Antithrombotic TherapyCirculation, 2019
- Atrial fibrillation and ischemic events with rivaroxaban in patients with stable coronary artery disease (AFIRE): Protocol for a multicenter, prospective, randomized, open-label, parallel group studyInternational Journal of Cardiology, 2018
- 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTSEuropean Heart Journal, 2017
- Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting StentsNew England Journal of Medicine, 2014
- Antiplatelet Therapy for Stable Coronary Artery Disease in Atrial Fibrillation Patients Taking an Oral AnticoagulantCirculation, 2014
- Very Late Stent Thrombosis and Late Target Lesion Revascularization After Sirolimus-Eluting Stent ImplantationCirculation, 2012
- Rivaroxaban in Patients with a Recent Acute Coronary SyndromeNew England Journal of Medicine, 2012
- Rivaroxaban versus Warfarin in Nonvalvular Atrial FibrillationNew England Journal of Medicine, 2011
- Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patientsJournal of Thrombosis and Haemostasis, 2005